Skip to main content
Top
Published in: Journal of Experimental & Clinical Cancer Research 1/2013

Open Access 01-12-2013 | Research

Osteopontin genetic variants are associated with overall survival in advanced non-small-cell lung cancer patients and bone metastasis

Authors: Yunzhen Chen, Haichun Liu, Wenliang Wu, Yi Li, Jianmin Li

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2013

Login to get access

Abstract

Purpose

Osteopontin (OPN) plays important roles in the modulation of apoptosis, angiogenesis, immune response, and tumor invasion. Elevated osteopontin expression has been reported in the lung cancer tissues compared to counterpart normal tissues. This study examined whether genetic variations in the osteopontin gene are associated with survival of lung cancer patients and occurrence rate of bone metastasis.

Experimental design

Three hundred and sixty patients with stages I to IV between 2003 and 2007 were recruited in this study and same number of healthy persons were used as control. Three promoter osteopontin polymorphisms, OPN-66 T/G, -156G/GG, and -443C/T variants were genotyped using DNA from blood lymphocytes. Chi-square test and a Fisher’s exact test were used to analyze the genotype distribution among TNM stages and incidence of bone metastasis and lymph mode metastasis. Kaplan-Meier method and log-rank test were used to compare survival by different genotypes.

Results

For the variant at nt −443 (CC), there was a significant difference between the number of patients with stage IV and those with all other stages of lung cancer (p < 0.01). Patients with −443 (CC) variant had significant higher incidence of bone metastasis development compared to other genotypes. For the variant at nt −443 (CT), there was a significant difference between the number of lung cancer patients with stage III + IV and those with stage I + II (P < 0.01). The survival rates for patients with the C/C genotype were significantly lower than for patients with the other two genotypes (C/T, T/T).

Conclusion

OSTEOPONTIN −443C/T polymorphism is a potential predictive marker of survival in lung cancer patients, it is correlated with bone metastasis significantly.
Appendix
Available only for authorised users
Literature
1.
go back to reference Shen H, Li Y, Liao Y, Zhang T, Liu Q, Du J: Lower blood calcium associates with unfavorable prognosis and predicts for bone metastasis in NSCLC. PLoS One. 2012, 7: e34264-10.1371/journal.pone.0034264.CrossRef Shen H, Li Y, Liao Y, Zhang T, Liu Q, Du J: Lower blood calcium associates with unfavorable prognosis and predicts for bone metastasis in NSCLC. PLoS One. 2012, 7: e34264-10.1371/journal.pone.0034264.CrossRef
2.
go back to reference Bi N, Yang M, Zhang L, Chen X, Ji W, Ou G, Lin D, Wang L: Cyclooxygenase-2 genetic variants are associated with survival in unresectable locally advanced non-small cell lung cancer. Clin Canc Res: an official journal of the American Association for Cancer Research. 2010, 16: 2383-2390. 10.1158/1078-0432.CCR-09-2793.CrossRef Bi N, Yang M, Zhang L, Chen X, Ji W, Ou G, Lin D, Wang L: Cyclooxygenase-2 genetic variants are associated with survival in unresectable locally advanced non-small cell lung cancer. Clin Canc Res: an official journal of the American Association for Cancer Research. 2010, 16: 2383-2390. 10.1158/1078-0432.CCR-09-2793.CrossRef
3.
go back to reference Gandara D, Narayan S, Lara PN, Goldberg Z, Davies A, Lau DH, Mack P, Gumerlock P, Vijayakumar S: Integration of novel therapeutics into combined modality therapy of locally advanced non-small cell lung cancer. Clin Canc Res: an official journal of the American Association for Cancer Research. 2005, 11: 5057s-5062s. 10.1158/1078-0432.CCR-05-9012.CrossRef Gandara D, Narayan S, Lara PN, Goldberg Z, Davies A, Lau DH, Mack P, Gumerlock P, Vijayakumar S: Integration of novel therapeutics into combined modality therapy of locally advanced non-small cell lung cancer. Clin Canc Res: an official journal of the American Association for Cancer Research. 2005, 11: 5057s-5062s. 10.1158/1078-0432.CCR-05-9012.CrossRef
4.
go back to reference Lee CB, Stinchcombe TE, Rosenman JG, Socinski MA: Therapeutic advances in local-regional therapy for stage III non-small-cell lung cancer: evolving role of dose-escalated conformal (3-dimensional) radiation therapy. Clin Lung Canc. 2006, 8: 195-202. 10.3816/CLC.2006.n.047.CrossRef Lee CB, Stinchcombe TE, Rosenman JG, Socinski MA: Therapeutic advances in local-regional therapy for stage III non-small-cell lung cancer: evolving role of dose-escalated conformal (3-dimensional) radiation therapy. Clin Lung Canc. 2006, 8: 195-202. 10.3816/CLC.2006.n.047.CrossRef
5.
go back to reference Liu SK, Olive PL, Bristow RG: Biomarkers for DNA DSB inhibitors and radiotherapy clinical trials. Cancer Metastasis Rev. 2008, 27: 445-458. 10.1007/s10555-008-9137-8.CrossRef Liu SK, Olive PL, Bristow RG: Biomarkers for DNA DSB inhibitors and radiotherapy clinical trials. Cancer Metastasis Rev. 2008, 27: 445-458. 10.1007/s10555-008-9137-8.CrossRef
6.
go back to reference Hashisako M, Wakamatsu K, Ikegame S, Kumazoe H, Nagata N, Kajiki A: Flare phenomenon following gefitinib treatment of lung adenocarcinoma with bone metastasis. Tohoku J Exp Med. 2012, 228: 163-168. 10.1620/tjem.228.163.CrossRef Hashisako M, Wakamatsu K, Ikegame S, Kumazoe H, Nagata N, Kajiki A: Flare phenomenon following gefitinib treatment of lung adenocarcinoma with bone metastasis. Tohoku J Exp Med. 2012, 228: 163-168. 10.1620/tjem.228.163.CrossRef
7.
go back to reference Pathi SP, Kowalczewski C, Tadipatri R, Fischbach C: A novel 3-D mineralized tumor model to study breast cancer bone metastasis. PLoS One. 2010, 5: e8849-10.1371/journal.pone.0008849.CrossRef Pathi SP, Kowalczewski C, Tadipatri R, Fischbach C: A novel 3-D mineralized tumor model to study breast cancer bone metastasis. PLoS One. 2010, 5: e8849-10.1371/journal.pone.0008849.CrossRef
8.
go back to reference Santini D, Schiavon G, Vincenzi B, Gaeta L, Pantano F, Russo A, Ortega C, Porta C, Galluzzo S, Armento G, et al: Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. PLoS One. 2011, 6: e19234-10.1371/journal.pone.0019234.CrossRef Santini D, Schiavon G, Vincenzi B, Gaeta L, Pantano F, Russo A, Ortega C, Porta C, Galluzzo S, Armento G, et al: Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. PLoS One. 2011, 6: e19234-10.1371/journal.pone.0019234.CrossRef
9.
go back to reference Coleman RE: Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Canc Res: an official journal of the American Association for Cancer Research. 2006, 12: 6243s-6249s. 10.1158/1078-0432.CCR-06-0931.CrossRef Coleman RE: Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Canc Res: an official journal of the American Association for Cancer Research. 2006, 12: 6243s-6249s. 10.1158/1078-0432.CCR-06-0931.CrossRef
10.
go back to reference Clezardin P, Teti A: Bone metastasis: pathogenesis and therapeutic implications. Clin Exp Metastasis. 2007, 24: 599-608. 10.1007/s10585-007-9112-8.CrossRef Clezardin P, Teti A: Bone metastasis: pathogenesis and therapeutic implications. Clin Exp Metastasis. 2007, 24: 599-608. 10.1007/s10585-007-9112-8.CrossRef
11.
go back to reference Vetrone SA, Montecino-Rodriguez E, Kudryashova E, Kramerova I, Hoffman EP, Liu SD, Miceli MC, Spencer MJ: Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF-beta. J Clin Invest. 2009, 119: 1583-1594. 10.1172/JCI37662.CrossRef Vetrone SA, Montecino-Rodriguez E, Kudryashova E, Kramerova I, Hoffman EP, Liu SD, Miceli MC, Spencer MJ: Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF-beta. J Clin Invest. 2009, 119: 1583-1594. 10.1172/JCI37662.CrossRef
12.
go back to reference Huan JL, Xing L, Qin XJ, Gao ZG, Pan XF, Zhao ZD: Expression and clinical significance of osteopontin in calcified breast tissue. Asian Pac J Cancer Prev. 2012, 13: 5219-5223. 10.7314/APJCP.2012.13.10.5219.CrossRef Huan JL, Xing L, Qin XJ, Gao ZG, Pan XF, Zhao ZD: Expression and clinical significance of osteopontin in calcified breast tissue. Asian Pac J Cancer Prev. 2012, 13: 5219-5223. 10.7314/APJCP.2012.13.10.5219.CrossRef
13.
go back to reference Senger DR, Perruzzi CA: Secreted phosphoprotein markers for neoplastic transformation of human epithelial and fibroblastic cells. Cancer Res. 1985, 45: 5818-5823. Senger DR, Perruzzi CA: Secreted phosphoprotein markers for neoplastic transformation of human epithelial and fibroblastic cells. Cancer Res. 1985, 45: 5818-5823.
14.
go back to reference Uaesoontrachoon K, Yoo HJ, Tudor EM, Pike RN, Mackie EJ, Pagel CN: Osteopontin and skeletal muscle myoblasts: association with muscle regeneration and regulation of myoblast function in vitro. Int J Biochem Cell Biol. 2008, 40: 2303-2314. 10.1016/j.biocel.2008.03.020.CrossRef Uaesoontrachoon K, Yoo HJ, Tudor EM, Pike RN, Mackie EJ, Pagel CN: Osteopontin and skeletal muscle myoblasts: association with muscle regeneration and regulation of myoblast function in vitro. Int J Biochem Cell Biol. 2008, 40: 2303-2314. 10.1016/j.biocel.2008.03.020.CrossRef
15.
go back to reference Staal A, van Wijnen AJ, Birkenhager JC, Pols HA, Prahl J, DeLuca H, Gaub MP, Lian JB, Stein GS, van Leeuwen JP, Stein JL: Distinct conformations of vitamin D receptor/retinoid X receptor-alpha heterodimers are specified by dinucleotide differences in the vitamin D-responsive elements of the osteocalcin and osteopontin genes. Mol Endocrinol. 1996, 10: 1444-1456. 10.1210/me.10.11.1444. Staal A, van Wijnen AJ, Birkenhager JC, Pols HA, Prahl J, DeLuca H, Gaub MP, Lian JB, Stein GS, van Leeuwen JP, Stein JL: Distinct conformations of vitamin D receptor/retinoid X receptor-alpha heterodimers are specified by dinucleotide differences in the vitamin D-responsive elements of the osteocalcin and osteopontin genes. Mol Endocrinol. 1996, 10: 1444-1456. 10.1210/me.10.11.1444.
16.
go back to reference Jin Y, Tong DY, Tang LY, Chen JN, Zhou J, Feng ZY, Shao CK: Expressions of Osteopontin (OPN), alphanubeta3 and Pim-1 Associated with Poor Prognosis in Non-small Cell Lung Cancer (NSCLC). Chin J Cancer Res. 2012, 24: 103-108. 10.1007/s11670-012-0103-1.CrossRef Jin Y, Tong DY, Tang LY, Chen JN, Zhou J, Feng ZY, Shao CK: Expressions of Osteopontin (OPN), alphanubeta3 and Pim-1 Associated with Poor Prognosis in Non-small Cell Lung Cancer (NSCLC). Chin J Cancer Res. 2012, 24: 103-108. 10.1007/s11670-012-0103-1.CrossRef
17.
go back to reference Chung JH, Park MS, Kim YS, Chang J, Kim JH, Kim SK: Usefulness of bone metabolic markers in the diagnosis of bone metastasis from lung cancer. Yonsei Med J. 2005, 46: 388-393. 10.3349/ymj.2005.46.3.388.CrossRef Chung JH, Park MS, Kim YS, Chang J, Kim JH, Kim SK: Usefulness of bone metabolic markers in the diagnosis of bone metastasis from lung cancer. Yonsei Med J. 2005, 46: 388-393. 10.3349/ymj.2005.46.3.388.CrossRef
18.
go back to reference Aruga A, Koizumi M, Hotta R, Takahashi S, Ogata E: Usefulness of bone metabolic markers in the diagnosis and follow-up of bone metastasis from lung cancer. Br J Cancer. 1997, 76: 760-764. 10.1038/bjc.1997.458.CrossRef Aruga A, Koizumi M, Hotta R, Takahashi S, Ogata E: Usefulness of bone metabolic markers in the diagnosis and follow-up of bone metastasis from lung cancer. Br J Cancer. 1997, 76: 760-764. 10.1038/bjc.1997.458.CrossRef
19.
go back to reference Zhao F, Chen X, Meng T, Hao B, Zhang Z, Zhang G: Genetic polymorphisms in the osteopontin promoter increases the risk of distance metastasis and death in Chinese patients with gastric cancer. BMC Cancer. 2012, 12: 477-10.1186/1471-2407-12-477.CrossRef Zhao F, Chen X, Meng T, Hao B, Zhang Z, Zhang G: Genetic polymorphisms in the osteopontin promoter increases the risk of distance metastasis and death in Chinese patients with gastric cancer. BMC Cancer. 2012, 12: 477-10.1186/1471-2407-12-477.CrossRef
20.
go back to reference Chiu YW, Tu HF, Wang IK, Wu CH, Chang KW, Liu TY, Kao SY: The implication of osteopontin (OPN) expression and genetic polymorphisms of OPN promoter in oral carcinogenesis. Oral Oncol. 2010, 46: 302-306. 10.1016/j.oraloncology.2010.01.018.CrossRef Chiu YW, Tu HF, Wang IK, Wu CH, Chang KW, Liu TY, Kao SY: The implication of osteopontin (OPN) expression and genetic polymorphisms of OPN promoter in oral carcinogenesis. Oral Oncol. 2010, 46: 302-306. 10.1016/j.oraloncology.2010.01.018.CrossRef
21.
go back to reference Rodrigues LR, Teixeira JA, Schmitt FL, Paulsson M, Lindmark-Mansson H: The role of osteopontin in tumor progression and metastasis in breast cancer. Canc Epidemiol Biomarkers Prev. 2007, 16: 1087-1097. 10.1158/1055-9965.EPI-06-1008.CrossRef Rodrigues LR, Teixeira JA, Schmitt FL, Paulsson M, Lindmark-Mansson H: The role of osteopontin in tumor progression and metastasis in breast cancer. Canc Epidemiol Biomarkers Prev. 2007, 16: 1087-1097. 10.1158/1055-9965.EPI-06-1008.CrossRef
22.
go back to reference Wai PY, Kuo PC: The role of osteopontin in tumor metastasis. J Surg Res. 2004, 121: 228-241. 10.1016/j.jss.2004.03.028.CrossRef Wai PY, Kuo PC: The role of osteopontin in tumor metastasis. J Surg Res. 2004, 121: 228-241. 10.1016/j.jss.2004.03.028.CrossRef
23.
go back to reference Bourguignon LY, Zhu H, Shao L, Zhu D, Chen YW: Rho-kinase (ROK) promotes CD44v(3,8-10)-ankyrin interaction and tumor cell migration in metastatic breast cancer cells. Cell Motil Cytoskeleton. 1999, 43: 269-287. 10.1002/(SICI)1097-0169(1999)43:4<269::AID-CM1>3.0.CO;2-5.CrossRef Bourguignon LY, Zhu H, Shao L, Zhu D, Chen YW: Rho-kinase (ROK) promotes CD44v(3,8-10)-ankyrin interaction and tumor cell migration in metastatic breast cancer cells. Cell Motil Cytoskeleton. 1999, 43: 269-287. 10.1002/(SICI)1097-0169(1999)43:4<269::AID-CM1>3.0.CO;2-5.CrossRef
24.
go back to reference Chu M, Yang P, Hu R, Hou S, Li F, Chen Y, Kijlstra A: Elevated serum osteopontin levels and genetic polymorphisms of osteopontin are associated with Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci. 2011, 52: 7084-7089. 10.1167/iovs.11-7539.CrossRef Chu M, Yang P, Hu R, Hou S, Li F, Chen Y, Kijlstra A: Elevated serum osteopontin levels and genetic polymorphisms of osteopontin are associated with Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci. 2011, 52: 7084-7089. 10.1167/iovs.11-7539.CrossRef
25.
go back to reference Alain K, Karrow NA, Thibault C, St-Pierre J, Lessard M, Bissonnette N: Osteopontin: an early innate immune marker of Escherichia coli mastitis harbors genetic polymorphisms with possible links with resistance to mastitis. BMC Genom. 2009, 10: 444-10.1186/1471-2164-10-444.CrossRef Alain K, Karrow NA, Thibault C, St-Pierre J, Lessard M, Bissonnette N: Osteopontin: an early innate immune marker of Escherichia coli mastitis harbors genetic polymorphisms with possible links with resistance to mastitis. BMC Genom. 2009, 10: 444-10.1186/1471-2164-10-444.CrossRef
26.
go back to reference Niino M, Kikuchi S, Fukazawa T, Yabe I, Tashiro K: Genetic polymorphisms of osteopontin in association with multiple sclerosis in Japanese patients. J Neuroimmunol. 2003, 136: 125-129. 10.1016/S0165-5728(03)00004-3.CrossRef Niino M, Kikuchi S, Fukazawa T, Yabe I, Tashiro K: Genetic polymorphisms of osteopontin in association with multiple sclerosis in Japanese patients. J Neuroimmunol. 2003, 136: 125-129. 10.1016/S0165-5728(03)00004-3.CrossRef
27.
go back to reference Wu CY, Wu MS, Chiang EP, Wu CC, Chen YJ, Chen CJ, Chi NH, Chen GH, Lin JT: Elevated plasma osteopontin associated with gastric cancer development, invasion and survival. Gut. 2007, 56: 782-789. 10.1136/gut.2006.109868.CrossRef Wu CY, Wu MS, Chiang EP, Wu CC, Chen YJ, Chen CJ, Chi NH, Chen GH, Lin JT: Elevated plasma osteopontin associated with gastric cancer development, invasion and survival. Gut. 2007, 56: 782-789. 10.1136/gut.2006.109868.CrossRef
28.
go back to reference Chang YS, Kim HJ, Chang J, Ahn CM, Kim SK: Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer. Lung Canc. 2007, 57: 373-380. 10.1016/j.lungcan.2007.04.005.CrossRef Chang YS, Kim HJ, Chang J, Ahn CM, Kim SK: Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer. Lung Canc. 2007, 57: 373-380. 10.1016/j.lungcan.2007.04.005.CrossRef
29.
go back to reference Brown LF, Papadopoulos-Sergiou A, Berse B, Manseau EJ, Tognazzi K, Perruzzi CA, Dvorak HF, Senger DR: Osteopontin expression and distribution in human carcinomas. Am J Pathol. 1994, 145: 610-623. Brown LF, Papadopoulos-Sergiou A, Berse B, Manseau EJ, Tognazzi K, Perruzzi CA, Dvorak HF, Senger DR: Osteopontin expression and distribution in human carcinomas. Am J Pathol. 1994, 145: 610-623.
30.
go back to reference Schultz J, Lorenz P, Ibrahim SM, Kundt G, Gross G, Kunz M: The functional -443T/C osteopontin promoter polymorphism influences osteopontin gene expression in melanoma cells via binding of c-Myb transcription factor. Mol Carcinog. 2009, 48: 14-23. 10.1002/mc.20452.CrossRef Schultz J, Lorenz P, Ibrahim SM, Kundt G, Gross G, Kunz M: The functional -443T/C osteopontin promoter polymorphism influences osteopontin gene expression in melanoma cells via binding of c-Myb transcription factor. Mol Carcinog. 2009, 48: 14-23. 10.1002/mc.20452.CrossRef
31.
go back to reference Iwasaki H, Shinohara Y, Ezura Y, Ishida R, Kodaira M, Kajita M, Nakajima T, Shiba T, Emi M: Thirteen single-nucleotide polymorphisms in the human osteopontin gene identified by sequencing of the entire gene in Japanese individuals. J Hum Genet. 2001, 46: 544-546. 10.1007/s100380170037.CrossRef Iwasaki H, Shinohara Y, Ezura Y, Ishida R, Kodaira M, Kajita M, Nakajima T, Shiba T, Emi M: Thirteen single-nucleotide polymorphisms in the human osteopontin gene identified by sequencing of the entire gene in Japanese individuals. J Hum Genet. 2001, 46: 544-546. 10.1007/s100380170037.CrossRef
Metadata
Title
Osteopontin genetic variants are associated with overall survival in advanced non-small-cell lung cancer patients and bone metastasis
Authors
Yunzhen Chen
Haichun Liu
Wenliang Wu
Yi Li
Jianmin Li
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2013
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/1756-9966-32-45

Other articles of this Issue 1/2013

Journal of Experimental & Clinical Cancer Research 1/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine